Repligen Corporation Set to Showcase Innovations at Key Events
WALTHAM, Mass. — Repligen Corporation (NASDAQ:RGEN), a prominent player in the life sciences sector, specializes in advancing bioprocessing technologies. The company recently announced its participation in three noteworthy investor conferences, demonstrating its ongoing commitment to the biopharmaceutical industry.
Upcoming Investor Conferences
Repligen will be featured in the following conferences, where its leadership team will engage in discussions and presentations:
The Wells Fargo Healthcare Conference
This conference is scheduled from September 3 to September 5 in Boston. Olivier Loeillot, the company’s President and Chief Executive Officer, will lead an analyst-led discussion on Thursday, September 4. The session begins bright and early at 8:00 a.m. ET, offering a valuable opportunity for insight into the company's strategic direction.
The Deutsche Bank Healthcare Summit
Taking place from September 10 to September 11 in New York, this summit will feature Jason Garland, the Chief Financial Officer of Repligen. He is set to participate in one-on-one meetings on September 10, where investors can engage with him on the company’s financial health and prospects.
The Bank of America Global Healthcare Conference
From September 23 to September 25 in London, UK, Olivier Loeillot will return to represent Repligen in an analyst-led discussion starting at 6:35 a.m. ET (11:35 a.m. BST) on September 25. This conference aims to foster conversations that drive the future of healthcare innovation.
Webcast Accessibility
For those unable to attend in person, Repligen will offer a live webcast of all conference presentations. Interested parties can access it via the company’s Investor Relations website, ensuring accessibility for all stakeholders. Additionally, recordings will be available for a limited time after the live events, providing another avenue for engagement.
About Repligen Corporation
Repligen Corporation stands at the forefront of bioprocessing technology, serving biopharmaceutical developers and contract development organizations worldwide. Their innovative solutions enhance the efficiency of manufacturing biological drugs. With a dedicated focus on filtration and fluid management, chromatography, process analytics, and proteins, Repligen is committed to inspiring advances in bioprocessing.
Headquartered in Waltham, Massachusetts, Repligen operates several manufacturing facilities across the U.S. and maintains key locations in Europe, including Estonia, France, Germany, Ireland, the Netherlands, and Sweden. The global footprint of Repligen reflects its dedication to supporting the needs of its clients in various markets.
For additional details about Repligen, visit their official website. Moreover, the company actively shares updates on platforms like LinkedIn, reflecting their approach to transparency and communication.
Contact Information:
For investors seeking further information, Jacob Johnson, VP of Investor Relations, is available at 781-419-0204. He can be reached via email for inquiries related to the company's performance and strategies.
Frequently Asked Questions
What events is Repligen Corporation participating in?
Repligen Corporation will attend the Wells Fargo Healthcare Conference, the Deutsche Bank Healthcare Summit, and the Bank of America Global Healthcare Conference.
Who will represent Repligen at these conferences?
Olivier Loeillot, President and CEO, and Jason Garland, CFO, will represent Repligen at these events.
How can investors access the conference presentations?
Investors can access the live webcast of the conference presentations on Repligen’s Investor Relations website.
What is Repligen Corporation known for?
Repligen Corporation is known for developing innovative bioprocessing technologies that facilitate the manufacturing of biological drugs.
Where is Repligen headquartered?
Repligen Corporation is headquartered in Waltham, Massachusetts, and has manufacturing sites both in the U.S. and Europe.
